Portal de Periódicos da CAPES

State of the art of Mohs surgery for rare cutaneous tumors in the Spanish Registry of Mohs Surgery (REGESMOHS)

2019; Wiley; Volume: 59; Issue: 3 Linguagem: Inglês

10.1111/ijd.14732

1365-4632

Pedro Rodríguez‐Jiménez, Yolanda Delgado Jiménez, Alejandra Reolid, O. Sanmartín‐Jiménez, Joan R. Garcés, M.Á. Rodríguez-Prieto, R. Miñano Medrano, Eva Vilarrasa, E. de Eusebio‐Murillo, Pedro Redondo, C. Ciudad‐Blanco, Victoriano Morales‐Gordillo, Agustí Toll, Juan L. Artola‐Igarza, M.L. Alonso Pacheco, I. Allende Markixana, R. Suárez‐Fernández, A. Alfaro Rubio, H. Vázquez‐Veiga, Á. Flórez-Menéndez, P. de la Cueva Dobao, Rafael Botella‐Estrada, B. García‐Bracamonte, L. Carnero‐González, Verónica Ruiz‐Salas, P. Sánchez‐Sambucety, J.L. López‐Estebaranz, Pilar Gil, Lucía Barchino, Matías Mayor Arenal, Izascun Ocerin‐Guerra, L. Hueso, María J. Seoane‐Pose, B. González‐Sixto, N. Cano-Martínez, Begoña Escutia‐Muñoz, Pablo L. Ortiz‐Romero, I. García‐Doval, M.Á. Descalzo,

Tumors and Oncological Cases

The use of Mohs micrographic surgery (MMS) for rare cutaneous tumors is poorly defined. We aim to describe the demographics, tumor presentation and topography, surgery characteristics and complications of MMS for rare cutaneous tumors in a national registry.Prospective cohort study of patients treated with MMS in Spain between July 2013 and June 2018. The inclusion criteria were patients with cutaneous tumors with final diagnosis different from basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, or any kind of melanoma.Five thousand and ninety patients were recorded in the registry, from which only 73 tumors (1.4%) fulfilled the inclusion criteria: atypical fibroxanthoma (18), microcystic adnexal carcinoma (10), extramammary Paget's disease (7), Merkel cell carcinoma (5), dermatofibroma (4), trichilemmal carcinoma (4), desmoplastic trichoepithelioma (4), sebaceous carcinoma (3), leiomyosarcoma (2), porocarcinoma (2), angiosarcoma (2), trichoblastoma (1), superficial acral fibromyxoma (1), and others (10). No intra-surgery morbidity was registered. Postsurgery complications appeared in six patients (9%) and were considered mild. Median follow-up time was 0.9 years during which three Merkel cell carcinomas, one angiosarcoma, one microcystic adnexal carcinoma, and four others recurred (12.3%).This national registry shows that rare cutaneous tumors represent a negligible part of the total MMS performed in our country with a low complication rate.